AntriaBio

AntriaBio is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
Company Growth (employees)
Type
Public
HQ
Louisville, US
Founded
2010
Size (employees)
19 (est)
AntriaBio was founded in 2010 and is headquartered in Louisville, US

AntriaBio Office Locations

AntriaBio has an office in Louisville
Louisville, US (HQ)
1450 Infinite Dr

AntriaBio Financials and Metrics

AntriaBio Financials

USD

Net income (Q1, 2018)

(6.7 m)

EBIT (Q1, 2018)

(6.7 m)

Market capitalization (31-Oct-2017)

53.7 m

Closing share price (31-Oct-2017)

1.1

Cash (30-Sep-2017)

4 m
AntriaBio's current market capitalization is $53.7 m.
USDFY, 2014FY, 2015FY, 2016

Sales and marketing expense

4.4 m

R&D expense

9.4 m

General and administrative expense

909.7 k

Operating expense total

14.7 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

5.3 k

Sales and marketing expense

358.5 k411.9 k591 k1 m678.6 k628.3 k865.2 k1.1 m1.2 m1.3 m1.9 m1.9 m1.5 m

R&D expense

2.2 k112.6 k1.6 m1.3 m2 m2.5 m2.3 m2.5 m3.1 m4.3 m

General and administrative expense

19.5 k7.5 k450.8 k164.6 k183.9 k87 k205.2 k198.5 k302.7 k256.6 k301.5 k382.5 k327.6 k
USDFY, 2014FY, 2015FY, 2016

Cash

5.9 m5.3 m4.1 m

Accounts Receivable

8.8 m

Inventories

289.6 k67.2 k

Current Assets

6.3 m6.1 m4.5 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

7441.1 m5.6 m4.3 m8.6 m8.2 m2.4 m1.7 m1.7 m3.4 m3.6 m4.4 m4 m

Inventories

223 k223 k223 k301.9 k76.1 k92.4 k186.8 k

Current Assets

576 k1.9 m6 m4.7 m8.7 m8.9 m3.1 m1.8 m2 m3.7 m3.8 m4.8 m4.4 m

Total Assets

863.6 k2.1 m6.3 m6.3 m10.7 m12.1 m9.2 m8.5 m8.8 m10.1 m9.9 m10.8 m9.8 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (9.7 m)(11.4 m)(14.9 m)

    Depreciation and Amortization

    7.8 k128.9 k744 k

    Inventories

    222.4 k

    Cash From Operating Activities

    (3.2 m)(7.1 m)(10.5 m)
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

    Net Income

    (819.5 k)(2.6 m)(7.7 m)(2.2 m)(5.2 m)(8.3 m)(3.3 m)(7.4 m)(11.1 m)(3.8 m)(8.7 m)(14.1 m)(6.7 m)

    Depreciation and Amortization

    27.4 k57.9 k91 k70.3 k220.5 k476.9 k268.4 k546.4 k829.3 k266.6 k

    Inventories

    213.5 k197.2 k

    Accounts Payable

    1.6 m
      Y, 2017

      Financial Leverage

      1.3 x
      Show all financial metrics

      AntriaBio Market Value History

      AntriaBio's Web-traffic and Trends

      AntriaBio Online and Social Media Presence

      AntriaBio Company Life and Culture

      You may also be interested in